Taurine 11 pp 71-85 | Cite as

Taurine Enhances the Protective Actions of Fish Oil Against D-Galactosamine-Induced Metabolic Changes and Hepatic Lipid Accumulation and Injury in the Rat

  • Yuanjun Shen
  • Cesar A. Lau-Cam
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1155)


This study has evaluated the effects of a supplementation with taurine (TAU) on the actions of fish oil (FO) against the hypoglycemia, hypoproteinemia, and hepatic accumulation of lipids and liver damage caused by D-galactosamine (GAL) in the rat. To this end, male Sprague-Dawley rats (200–225 g), in groups of 6, were orally treated with physiological saline (2.5 mL, control group), FO (60 mg/kg), TAU (2.4 mmol/kg) or FO-TAU for three consecutive days and before a single oral dose of GAL (400 mg/kg) given on day 3. In parallel, rats receiving only GAL on day 3 or N-acetylcysteine (NAC, 2.4 mmol/kg) for 3 days before GAL served as controls. On day 4 blood samples were collected by cardiac puncture and used to either measure glucose (GLC) or to obtain plasma fractions. Immediately thereafter, the livers were excised, made into a homogenate in phosphate buffered saline pH 7.4, and centrifuged to obtain clear supernatant. Plasma samples were assayed for their total protein (TP), triglycerides (TG), cholesterol (CHOL), phospholipids (PLP), free fatty acids (FFA) and total bilirubin (TB) and direct bilirubin (DB) contents, and for the activities of alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP). The liver homogenates were used to measure TG, CHOL, PLP and total lipids (TL) contents. Without exceptions, GAL was found to markedly affect (p < 0.001) all of the experimental parameters examined, with increases occurring in all instances except for the values of the plasma GLC, TP and PLP which were decreased. A pretreatment with either FO or TAU led to significant attenuation of the effects of GAL and which, in most cases, were of similar magnitude. On the other hand, a combined pretreatment with FO plus TAU usually resulted in a greater protection than with either agent alone (p ≤ 0.05). NAC, serving as a reference treatment, was, in most instances, equipotent with FO alone and. in addition, was the only agent that significantly attenuated the increases in both liver weight and liver weight to body weight ratio caused by GAL.


Galactosamine Fish oil Taurine Plasma glucose Total protein Bilirubin Alanine aminotransferase Aspartate aminotransferase Alkaline phosphatase Plasma and liver lipids 



Alkaline phosphatase


Alanine aminotransferase


Aspartate aminotransferase




Direct bilirubin


Free fatty acids


Fish oil












Total bilirubin


Total lipids


Total protein


  1. Al-Tuwaijri A, Akdamar K, di Luzio NR (1981) Modification of galactosamine-induced liver injury in rats by reticuloendothelial system stimulation or depression. Hepatology 1:107–113CrossRefGoogle Scholar
  2. Ando K, Nagata K, Yoshida R, Kikugawa K, Suzuki M (2000) Effect of n-3 polyunsaturated fatty acid supplementation on lipid peroxidation of rat organs. Lipids 35:401–407CrossRefGoogle Scholar
  3. Aristatile B, Al-Numair KS, Veeramani C, Pugalendi KV (2009) Effect of carvacrol on hepatic marker enzymes and antioxidant status in D-galactosamine-induced hepatotoxicity in rats. Fundam Clin Pharmacol 23:757–765Google Scholar
  4. Asha KK, Devadasan K (2013) Protective effect of taurine on the mitochondria of albino rats induced with fulminant hepatic failure. Biomed Prev Med 3:279–283CrossRefGoogle Scholar
  5. Cartwright CK, Ragland JB, Weidman SW, Sabesin SM (1982) Alterations in lipoprotein composition associated with galactosamine-induced rat liver injury. J Lipid Res 23:667–679PubMedGoogle Scholar
  6. Decker K, Keppler D (1974) Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 71:77–106CrossRefGoogle Scholar
  7. Diaz-Buxo JA, Blumenthal S, Hayes D, Gores P, Gordon B (1997) Galactosamine-induced fulminant hepatic necrosis in unanesthetized canines. Hepatology 25:950–957CrossRefGoogle Scholar
  8. Dossi CG, Tapia GS, Espinosa A, Videla LA, D’Espessailles A (2014) Reversal of high-fat diet-induce hepatic steatosis by n-3 LCPUFA: a role of PPAR-α and SREBP-1c. J Nutr Biochem 25:977–984CrossRefGoogle Scholar
  9. El-Mofty SK, Scrutton MC, Serroni A, Nicolini C, Farber JL (1975) Early, reversible plasma membrane injury in galactosamine -induced liver cell death. Am J Pathol 79:579–596PubMedPubMedCentralGoogle Scholar
  10. Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT, Wang D, Wei Y, Jiang H, Orlicky DJ, Petersen DR et al (2011) Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 301:R1710–R1722CrossRefGoogle Scholar
  11. Heidari R, Jamshidzadeh A, Niknahad H, Mardani E, Ommati MM, Azarpira N, Khodaei N, Zarei A, Ayarzadeh M, Mousavi S et al (2016) Effect of taurine on chronic and acute liver injury: focus on blood and brain ammonia. Toxicol Rep 13:3870–3879Google Scholar
  12. Keppler D, Decker K (1969) Studies on the mechanism of galactosamine hepatitis: accumulation of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 10:219–225CrossRefGoogle Scholar
  13. Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA (1999) Reversal of ethanol-induced hepatic steatosis and lipid peroxidation by taurine: a study in rats. Alcohol 34:529–541CrossRefGoogle Scholar
  14. Kikugawa K, Yasuhara Y, Ando K, Koyama K, Hiramoto K, Suzuki M (2003) Protective effect of supplementation of fish oil with n-3 polyunsaturated fatty acids against oxidative stress-induced DNA damage of rat liver in vivo. J Agric Food Chem 51:6073–6079CrossRefGoogle Scholar
  15. Lee EW, He P, Kawagishi H, Sugiyama K (2000) Suppression of D-galactosamine-induced liver injury by mushrooms in rats. Biosci Biotechnol Biochem 64:2001–2004CrossRefGoogle Scholar
  16. MacDonald JR, Gandolfi AJ, Sipes G (1985) Structural requirements for cytoprotective agents in galactosamine-induced hepatic necrosis. Toxicol Appl Pharmacol 81:17–24CrossRefGoogle Scholar
  17. McIntyre N (1978) Plasma lipids and lipoproteins in liver disease. Gut 19:526–530CrossRefGoogle Scholar
  18. Mészáros K, Mandl J, Antoni F, Garzó T (1976) Inhibition of protein synthesis by hexosamine containing glycogen formed in mouse liver after treatment with D-galactosamine. FEBS Lett 71:215–219CrossRefGoogle Scholar
  19. Oarada M, Tsuzuki T, Gonoi T, Igarashi M, Kamei K, Nikawa T, Hirasaka K, Ogawa Y, Miyazawa T, Nakagawa K, Kurita N (2008) Effects of dietary fish oil on lipid peroxidation and serum triacylglycerol levels in psychologically stressed mice. Nutrition 24:67–75CrossRefGoogle Scholar
  20. Okada T, Kawakami S, Nakamura Y, Han KH, Ohba K, Aritsuka T, Uchino H, Shimada K, Sekikawa M, Ishii H, Fukushima M (2011) Amelioration of D-galactosamine-induced acute liver injury in rats by dietary supplementation with betaine derived from sugar beet molasses. Biosci Biotechnol Biochem 75:1335–1341CrossRefGoogle Scholar
  21. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J et al (2009) Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 1792:1080–1086CrossRefGoogle Scholar
  22. Pushpakiran G, Mahalakshmi K, Viswanathan P, Anuradha CV (2005) Taurine prevents ethanol-induced alterations in lipoids and ATPases in rat tissues. Pharmacol Rep 57:578–587PubMedGoogle Scholar
  23. Radhiga T, Sundaresan A, Viswanathan P, Pugalendi KV (2016) Effect of protocatechuic acid on lipid profile and DNA damage in D-galactosamine-induced hepatotoxic rats. J Basic Clin Physiol Pharmacol 27:505–514CrossRefGoogle Scholar
  24. Ravikumar V, Shivashangari KS, Devaki T, Ethnopharmacol J (2005) Hepatoprotective activity of Tridax procumbens against D-galactosamine/lipopolysaccharide-induced hepatitis in rats. J Ethnopharmacol 101:55–60CrossRefGoogle Scholar
  25. Roy P, Chandrasekhar D, Pujari P (2007) Dietary fish oil as hepatoprotective agent in Mus musculus. Indian J Exp Biol 405:367–370Google Scholar
  26. Saracyn M, Zdanowski R, Brytan M, Kade G, Novak Z, Patera J, Dyrla P, Gil J, Wańkowicz Z (2015) D-Galactosamine intoxication in experimental animals: is it only an experimental model of acute liver failure? Med Sci Monit 21:1469–1477CrossRefGoogle Scholar
  27. Sathivel A, Raghavendran HRB, Srinivasan P, Devaki T (2008) Anti-peroxidative and anti-hyperlipidemic nature of Ulva lactuca crude polysaccharide on D-galactosamine induced hepatitis in rats. Food Chem Toxicol 46:3262–3267CrossRefGoogle Scholar
  28. Schmöcker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, Berg T, Kang JX (2007) Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology 45:864–869CrossRefGoogle Scholar
  29. Shanmugarajan TS, Sivaraman D, Somasundaram I, Arunsundar M, Krishna-kumar E, Balaji R, Ravichandiran V (2008) Influence of alpha lipoic acid on antioxidant status in D-galactosamine-induced hepatic injury. Toxicol Ind Health 24:635–642CrossRefGoogle Scholar
  30. Shin JH, Lee CW, Oh SJ, Yun J, Kang MR, Han SB, Park H, Jung JC, Chung YH, Kang JS (2014) Hepatoprotective effect of aged black garlic extract in rodents. Toxicol Res 30:49–54CrossRefGoogle Scholar
  31. Stramentinoli G, Gualano M, Ideo G (1978) Protective role of S-adenosyl-L-methionine on liver injury induced by D-galactosamine in rats. Biochem Pharmacol 27:1431–1433CrossRefGoogle Scholar
  32. Sugiyama K, He P, Wada S, Tamaki F, Saeki S (1988) Green tea suppresses D-galactosamine-induced liver injury in rats. Biosci Biotechnol Biochem 62:609-611CrossRefGoogle Scholar
  33. Sugiyama K, He P, Wada S, Tamaki F, Saeki S (1998) Green tea suppresses D-Galactosamine-induced liver injury in rats. Biosci Biotechnol Biochem 62(3):609–611CrossRefGoogle Scholar
  34. Sugiyama K, He P, Wada S, Saeki S (1999) Teas and other beverages suppress D-galactosamine-induced liver injury in rats. J Nutr 129:1361–1367CrossRefGoogle Scholar
  35. Tapia G, Valenzuela R, Espinosa A, Romanque P, Dossi C, Gonzalez-Mañán D, Videla LA, D’Espessailles A (2014) N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation. Mol Nutr Food Res 58:1333–1341CrossRefGoogle Scholar
  36. Timbrell JA, Waterfield CJ (1996) Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. Adv Exp Med Biol 403:125–134CrossRefGoogle Scholar
  37. Timbrell JA, Seabra V, Waterfield CJ (1995) The in vivo and in vitro protective properties of taurine. Gen Pharmacol 26:453–462CrossRefGoogle Scholar
  38. Valenzuela R, Espinosa A, González-Mañán D, D’Espessailles A, Fernández V, Videla LA, Tapia G (2012) N-3 Long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One 7:e46400CrossRefGoogle Scholar
  39. Waterfield CJ, Turton JA, Scales MD, Timbrell JA (1991) Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats. Arch Toxicol 65:548–555CrossRefGoogle Scholar
  40. Waterfield CJ, Turton JA, Scales MD, Timbrell JA (1993) Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats. Arch Toxicol 67:244-254CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Yuanjun Shen
    • 1
  • Cesar A. Lau-Cam
    • 1
  1. 1.Department of Pharmaceutical Sciences, College of Pharmacy and Health ProfessionsSt. John’s UniversityJamaicaUSA

Personalised recommendations